- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04413682
Telerehabilitation vs Supervised Exercises in MS
May 30, 2020 updated by: Ela Tarakci, Istanbul University
Effectiveness of Structured Exercise Program on Quality of Life and Activities of Daily Living in Persons With Multiple Sclerosis: Telerehabilitation vs Supervised Program
Multiple sclerosis (MS) is a complex neurodegenerative autoimmune disease.
People with MS (PwMS) have low quality of life (QoL) and activities of daily living (ADL).
Exercise is a safe and effective rehabilitation tool for PwMS.
A structured and personalized exercise program can improve physical fitness, functional capacity, quality of life and modifiable disorders in PwMS.
On the other hand, Telerehabilitation is an alternative rehabilitation method in PwMS.
The purpose of this study is to investigate the effectiveness of exercise programs and telerehabilitation on ADL and QoL in PwMS, and compare the effects of supervised exercise and home-based exercise programs for the PwMS.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Participants are randomly assigned to the structured supervised exercise or structured home-based groups.
Interventions in Group 1 (n=15) includes one session per day, 3 days a week over a 12-weeks structured exercise program under the supervision of a physical therapist.
Group 2 (n=15) includes a 12-week structured home-based exercise program checked and controlled through telerehabilitation three times a week.
All measurements pre-post intervention.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey, 34815
- Istanbul University-Cerrahpasa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
patients with:
- Stable period at the time of application to the clinic
- Expanded Disability Status Scale Levels between 2 - 6.5
- Appropriate cognitive level to understand the exercises
- No diseases to affect their participation in exercise programs
Exclusion Criteria:
patients with:
- Poorly controlled diabetes, hypertension or other medical conditions to be incompatible with study participation,
- A new history of previous attacks
- No reliable informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Supervised Exercise Group
One session per day, 3 days per week over a 12-weeks structured exercise program under supervision of a physical therapist.
|
Structured Exercise Program under the supervision of Physical Therapist
|
Experimental: Telerehabilitation Group
One session per day, 3 days per week over a 12-weeks structured exercise program through Telerehabilitation
|
Structured Exercise Program checked and controlled through telerehabilitation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Independence Measure (FIM)
Time Frame: Changes after 12 weeks
|
FIM is a tool used for evaluation of primary ADL of people with disability.
FIM items include self care, sphincter control, transfers, locomotion, communication, and social cognition subgroups.
Grading is based on 7 points.
7: complete independence, 6: modified independence, 5, 4 and 3: modified dependence, 2 and 1: complete dependence.
|
Changes after 12 weeks
|
Nottingham Health Profile, First section (NHP-I)
Time Frame: Changes after 12 weeks
|
NHP is a tool used for measuring and definition of QoL regarding the health status in general.
NHP-I contains 38 yes/no statements, focusing on different aspects of the general health problems, including six dimensions of subjective health defined as physical abilities, pain, sleep, energy, emotional reaction, energy level and social isolation.
Questions are evaluated according to the patients' yes/no responses and are scored between 0 and 100.
High scores indicate high level health status in the specified item.
Total scores are summed in all fields.
|
Changes after 12 weeks
|
Quality of life scale (QoLS)
Time Frame: Changes after 12 weeks
|
QoLS is a standardized interview consisting of 41 questions clustered in four subscales: functional and economic scale, social and recreational scale, affect and life in general scale, and medical problems scale.
Each question in the scale is evaluated over 5 points.
(1 is negative at all times and 5 is the best response).
|
Changes after 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ela Tarakci, Professor, etarakci@istanbul.edu.tr
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2019
Primary Completion (Actual)
February 10, 2020
Study Completion (Actual)
May 30, 2020
Study Registration Dates
First Submitted
May 30, 2020
First Submitted That Met QC Criteria
May 30, 2020
First Posted (Actual)
June 4, 2020
Study Record Updates
Last Update Posted (Actual)
June 4, 2020
Last Update Submitted That Met QC Criteria
May 30, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS-TeleRehab2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Structured Supervised Exercise
-
University of PadovaCompleted
-
Nordsjaellands HospitalUniversity of Copenhagen; University of Aarhus; Deakin University; Technical University... and other collaboratorsCompletedPhysical Activity | Pregnancy RelatedDenmark
-
University of ManchesterUnknownCardiovascular Diseases | Peripheral Arterial Disease
-
Hull University Teaching Hospitals NHS TrustCompletedAbdominal Aortic AneurysmUnited Kingdom
-
Universidad de AlmeriaCompletedLow Back Pain | Physical ActivitySpain
-
Medical University of ViennaUnknownPeripheral Artery DiseaseAustria
-
Hasselt UniversityRecruitingGestational Hypertension | Cardiovascular Pregnancy ComplicationBelgium
-
University Health Network, TorontoCompletedProstate CancerCanada
-
Grupo Rehabilitacion en SaludClinica Las AmericasCompletedChronic Heart FailureColombia
-
Hospital General de México Dr. Eduardo LiceagaNational Council of Science and Technology, Mexico; Universidad Nacional Autonoma... and other collaboratorsUnknownLiver Diseases | Obesity | Metabolic Syndrome | Exercise | Childhood Obesity | Cardiovascular Risk FactorMexico